Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco's Clinical Research Organization - AnaCipher receives accreditation from UKMHRA27-08-2021
27-08-2021
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investors Meet21-08-2021
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investors Meet20-08-2021
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Un-Audited Financial Results for the quarter ended 30.06.202112-08-2021
Indoco Remedies zooms 20%, hits record high on strong Q1 results
Indoco is expected to post strong FY22 top line growth as Domestic sales normalize and grow amid opportunities arising out of post-Covid complications, ICICI Securities said12-08-2021
Indoco Remedies Ltd - 532612 - Audio Recording Of Conference Call Held On August 11, 2021
Audio recording of Conference Call held on August 11, 202111-08-2021
Earnings Call for Q1FY22 of Indoco Remedies
Conference Call with Indoco Remedies Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.11-08-2021
Q1FY22 Result Announced for Indoco Remedies Ltd.
Indoco’s revenues grow at 43%, EBIDTA jumps 78 % in Q1FY22: During the first quarter of FY 2021-22, revenues of Indoco Remedies grew by 42.9 % at Rs. 381.2 crores, as against Rs. 266.8 crores, same quarter last year. EBIDTA to net sales for the quarter is 22.8 % at Rs. 86.8 crores, compared to 18.3 % at Rs. 48.9 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 10.4 % at Rs. 39.6 crores, compared to 6.5 % at Rs.17.2 crores, same quarter last year. Commenting on the first quarter FY22 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “Our India & International Businesses have shown a robust growth this quarter. We have optimised the opportunities presented by this very dynamic business environment as well as effectively adapted to the challenges thus presented”. Result PDF11-08-2021
INDOCO REMEDIES LTD. - 532612 - UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30.06.2021
UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30.06.202111-08-2021
Indoco Remedies Ltd - 532612 - SCHEDULE OF CONCALL MEETING {UNDER REG 30 -(LODR)}
SCHEDULE OF CONCALL MEETING28-07-2021